Top

Cancer Immunology, Immunotherapy

Published in:

01-04-2008 | Original Article

CXCR5 may be involved in the attraction of human metastatic neuroblastoma cells to the bone marrow

Authors: Irma Airoldi, Claudia Cocco, Fabio Morandi, Ignazia Prigione, Vito Pistoia

Published in: Cancer Immunology, Immunotherapy | Issue 4/2008

Abstract

Introduction

Up-regulation of some chemokine receptors on tumor cells is associated with increased metastatic potential. In this respect, limited information is available on chemokine receptor in human neuroblastoma (NB).

Objects

Purpose of the study was to identify chemokines/chemokine receptors involved in bone marrow (BM) localization of metastatic NB cells in view of the development of targeted therapeutic strategies. CD45⁻ metastatic NB cells were isolated from the BM of six patients by immunomagnetic bead manipulation. Some experiments were carried out using a panel of human neuroblastoma cell lines (GI-ME-N, GI-LI-N, LAN-5, HTLA-230, SH-SY-5Y and IMR-32). Immunophenotypic analyses were performed by flow cytometry. Cell migration assays were carried out using transwell systems. Calcium ion mobilization, chemokine receptor internalization and cell proliferation were investigated by flow cytometry.

Results

In all BM samples, CXCR5 was expressed by the majority of primary neuroblasts and mediated their chemotaxis in response to CXCL13. Primary metastatic NB cells from all BM samples expressed CXCR6, but were not attracted by soluble CXCL16. Studies performed with two CXCR6⁺ NB cell lines showed that the mechanism whereby neuroblasts did not migrate to CXCL16 was likely related to defective calcium ion mobilization.

Conclusions

CXCR5 is the first chemokine receptor so far identified able to attract in vitro primary metastatic NB cells. CXCR6 may be involved in retention of metastatic neuroblasts in the BM through interaction with CXCL16 expressing stromal cells in the absence of signal transduction.

Brodeur GM (2003) Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 3:203–216PubMedCrossRef

Cotterill SJ, Pearson AD, Pritchard J, Kohler JA, Foot AB (2001) Late relapse and prognosis for neuroblastoma patients surviving 5 years or more: a report from the European Neuroblastoma Study Group “Survey”. Med Pediatr Oncol 36:235–238PubMedCrossRef

Honczarenko M, Le Y, Swierkowski M, Ghiran I, Glodek AM, Silberstein LE (2006) Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors. Stem Cells 24:1030–1041PubMedCrossRef

Katschke KJ Jr, Rottman JB, Ruth JH et al (2001) Differential expression of chemokine receptors on peripheral blood, synovial fluid, and synovial tissue monocytes/macrophages in rheumatoid arthritis. Arthritis Rheum 44:1022–1032PubMedCrossRef

Qin S, Rottman JB, Myers P et al (1998) The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest 101:746–754PubMedCrossRef

Zlotnik A, Yoshie O (2000) Chemokines: a new classification system and their role in immunity. Immunity 12:121–127PubMedCrossRef

Schioppa T, Uranchimeg B, Saccani A et al (2003) Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med 198:1391–1402PubMedCrossRef

Muller A, Homey B, Soto H et al (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410:50–56PubMedCrossRef

Murphy PM (2001) Chemokines and the molecular basis of cancer metastasis. N Engl J Med 345:833–835PubMedCrossRef

10.

Pistoia V, Corcione A, Dallegri F, Ottonello L (2006) Lymphoproliferative disorders and chemokines. Curr Drug Targets 7:81–90PubMedCrossRef

11.

Balkwill F (2004) Cancer and the chemokine network. Nat Rev Cancer 4:540–550PubMedCrossRef

12.

Airoldi I, Raffaghello L, Piovan E, Cocco C, Carlini B, Amadori A, Corrias MV, Pistoia V (2006) CXCL12 does not attract CXCR4+ human metastatic neuroblastoma cells: clinical implications. Clin Cancer Res 12:77–82PubMedCrossRef

13.

Geminder H, Sagi-Assif O, Goldberg L, Meshel T, Rechavi G, Witz IP, Ben-Baruch A (2001) A possible role for CXCR4 and its ligand, the CXC chemokine stromal cell-derived factor-1, in the development of bone marrow metastases in neuroblastoma. J Immunol 167:4747–4757PubMed

14.

Metelitsa LS, Wu HW, Wang H et al (2004) Natural killer T cells infiltrate neuroblastomas expressing the chemokine CCL2. J Exp Med 199:1213–1221PubMedCrossRef

15.

Ferrer FA, Pantschenko AG, Miller LJ, Anderson K, Grunnet M, McKenna PH, Kreutzer D (2000) Angiogenesis and neuroblastomas: interleukin-8 and interleukin-8 receptor expression in human neuroblastoma. J Urol 164:1016–1020PubMedCrossRef

16.

Goldberg-Bittman L, Sagi-Assif O, Meshel T, Nevo I, Levy-Nissenbaum O, Yron I, Witz IP, Ben-Baruch A (2005) Cellular characteristics of neuroblastoma cells: regulation by the ELR–CXC chemokine CXCL10 and expression of a CXCR3-like receptor. Cytokine 29:105–117PubMedCrossRef

17.

Brodeur GM, Pritchard J, Berthold F et al (1993) Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11:1466–1477PubMed

18.

Puppo M, Pastorino S, Melillo G, Pezzolo A, Varesio L, Bosco MC (2004) Induction of apoptosis by flavopiridol in human neuroblastoma cells is enhanced under hypoxia and associated with N-myc proto-oncogene down-regulation. Clin Cancer Res 10:8704–8719PubMedCrossRef

19.

Flynn G, Maru S, Loughlin J, Romero IA, Male D (2003) Regulation of chemokine receptor expression in human microglia and astrocytes. J Neuroimmunol 136:84–93PubMedCrossRef

20.

Meijer J, Zeelenberg IS, Sipos B, Roos E (2006) The CXCR5 chemokine receptor is expressed by carcinoma cells and promotes growth of colon carcinoma in the liver. Cancer Res 66:9576–9582PubMedCrossRef

21.

Ou DL, Chen CL, Lin SB, Hsu CH, Lin LI (2006) Chemokine receptor expression profiles in nasopharyngeal carcinoma and their association with metastasis and radiotherapy. J Pathol 210:363–373PubMedCrossRef

22.

Seidl H, Richtig E, Tilz H et al (2007) Profiles of chemokine receptors in melanocytic lesions: de novo expression of CXCR6 in melanoma. Hum Pathol 38(5):768–780PubMedCrossRef

23.

Russell HV, Hicks J, Okcu MF, Nuchtern JG (2004) CXCR4 expression in neuroblastoma primary tumors is associated with clinical presentation of bone and bone marrow metastases. J Pediatr Surg 39:1506–1511PubMedCrossRef

24.

Smith JR, Braziel RM, Paoletti S, Lipp M, Uguccioni M, Rosenbaum JT (2003) Expression of B-cell-attracting chemokine 1 (CXCL13) by malignant lymphocytes and vascular endothelium in primary central nervous system lymphoma. Blood 101:815–821PubMedCrossRef

25.

Baggiolini M (1998) Chemokines and leukocyte traffic. Nature 392:565–568PubMedCrossRef

26.

Lisignoli G, Cristino S, Toneguzzi S, Grassi F, Piacentini A, Cavallo C, Facchini A, Mariani E (2004) IL1beta and TNFalpha differently modulate CXCL13 chemokine in stromal cells and osteoblasts isolated from osteoarthritis patients: evidence of changes associated to cell maturation. Exp Gerontol 39:659–665PubMedCrossRef

27.

Haskell CA, Cleary MD, Charo IF (1999) Molecular uncoupling of fractalkine-mediated cell adhesion and signal transduction. Rapid flow arrest of CX3CR1-expressing cells is independent of G-protein activation. J Biol Chem 274:10053–10058PubMedCrossRef

Title: CXCR5 may be involved in the attraction of human metastatic neuroblastoma cells to the bone marrow
Authors: Irma Airoldi
Claudia Cocco
Fabio Morandi
Ignazia Prigione
Vito Pistoia
Publication date: 01-04-2008
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 4/2008
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-007-0392-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Objects

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2008

CpG-ODN but not other TLR-ligands restore the antitumor responses in old mice: the implications for vaccinations in the aged

Saccharomyces cerevisiae, the Baker’s Yeast, suppresses the growth of Ehrlich carcinoma-bearing mice

Transient downregulation of monocyte-derived dendritic-cell differentiation, function, and survival during tumoral progression and regression in an in vivo canine model of transmissible venereal tumor

Priming of naive CD8+ T cells in the presence of IL-12 selectively enhances the survival of CD8+CD62Lhi cells and results in superior anti-tumor activity in a tolerogenic murine model

Vγ9Vδ2 T cell-mediated recognition of human solid tumors. Potential for immunotherapy of hepatocellular and colorectal carcinomas

Progress in vaccination against cancer-7: report of the meeting in Stockholm, September 10–11, 2007

Keynote webinar | Spotlight on antibody–drug conjugates in cancer